Preferences
Privacy is important to us, so you have the option of disabling certain types of storage that may not be necessary for the basic functioning of the website. Blocking categories may impact your experience on the website. More information
Privacy is important to us, so you have the option of disabling certain types of storage that may not be necessary for the basic functioning of the website. Blocking categories may impact your experience on the website. More information
🔬 Predictive oncology in the spotlight at ESMO #MAP2025.
💡 Our CSO, Frederic Saltel, and Deputy CTO, Hadrien Mary, were at the conference to present our work on predicting treatment response in advanced liver cancer. With first-line therapies failing in up to 70% of cases, oncologists urgently need better tools. Our research shows how proteomic signatures can provide the biological rationale that is currently missing.
🚀 At BeLiver, we are committed to translating this science into a clinical reality to improve patient survival and quality of life. Our goal is simple: to give every patient the best chance of success, right from the first treatment.
